efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,
The study aims to assess Sofosbuvir containing regimens in treatment of COVID-19 Egyptian
patients,
Drug: Sofosbuvir
Sofosbuvir once daily
Other Name: Mpiviropack, Sovaldy, soflanork
Drug: Daclatasvir
daclatasuvir once daily
Other Name: daklinza, daklanork
Inclusion Criteria:
- COVID 19 positive patients
Exclusion Criteria:
- COVID-19 patients with critical manifestations.
- Sepsis.
- Acute respiratory distress syndrome (ARDS).
- Decompensated liver disease (Child-Pugh class B or C disease).
- Chronic renal impairment.
- Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ….).
- Ischemic heart disease within the last 6 months.
- Chronic pulmonary disease.
- Malignancy.
- Pregnancy or breastfeeding.
- Hypersensitivity to sofosbuvir or ribavirin.
- Patients with organ transplant.
- Unwilling to participate in our study
Cairo and Tanta Universitities
Tanta, Egypt
Investigator: sherief abd-elsalam, ass. prof
Contact: 00201147773440
sheriefabdelsalam@yahoo.com
Sherief Abd-Elsalam, ass. prof.
00201147773440
sheriefabdelsalam@yahoo.com
sherief abd-elsalan, ass. prof.
00201147773440
sheriefabdelsalam@yahoo.com